Normal-phase and stability-indicating reversed-phase high-performance liquid chromatographic methods for the determination of the novel antitumor agent: 1-methylpropyl-2-imidazolyldisulfide

被引：3

作者：

Hashash, A

Kirkpatrick, DL

Egorin, MJ

Block, LH

Lazo, JS

机构：

[1] Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA

[2] Duquesne Univ, Grad Sch Pharmaceut Sci, Pittsburgh, PA 15282 USA

[3] Prolx Pharmaceut, Pittsburgh, PA 15219 USA

来源：

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2002年 / 768卷 / 02期

关键词：

1-methylpropyl-2-imidazolyldisulphide;

D O I：

10.1016/S1570-0232(01)00584-0

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

1-Methylpropyl-2-imidazolyl disulfide (MID) is a novel antitumor agent currently in Phase I clinical trials. The chromatographic behavior of MID and its potential impurity, degradation product, and metabolite 2-mercaptoimidazole (2MI) was studied under reversed-phase (RP) and normal-phase (NP) conditions. Both RP- and NP-HPLC separation methods were developed. RP-HPLC was validated as a stability-indicating assay for MID. NP-HPLC retained both MID and 2MI and pending further validation, could prove useful in the study of MID pharmacokinetics. (C) 2002 Elsevier Science B.V. All rights reserved.

引用

页码：239 / 246

页数：8

共 8 条

[1]

HASHASH A, 2001, 92 ANN M AM ASS CANC, V42

[2]

Kirkpatrick DL, 1999, ANTI-CANCER DRUG DES, V14, P421

[3] Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides [J].